Atezolizumab+Bevacizumab+SBRT in Unresectable HCC

• Status: Not yet recruiting
• Trial end date: 2026-01-01

Summary

This research study is evaluating the safety and tolerability of the drugs atezolizumab and bevacizumab with stereotactic body radiation therapy (SBRT) for treating unresectable hepatocellular carcinoma.

This study involves the following interventions:

• Atezolizumab

• Bevacizumab

• Stereotactic body radiation therapy (SBRT)

• Phase: Phase 1

Details

• Lead Sponsor: Massachusetts General Hospital
• Collaborator: Genentech, Inc.
• Treatments: Atezolizumab; Bevacizumab